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RhoGEFs (guanine nucleotide exchange factors of the
Rho GTPase family) are upstream regulators of cell
adhesion and migration pathways, thus representing
attractive yet relatively unexplored targets for the
development of anti-invasive drugs. We screened
for chemical inhibitors of TrioN, the N-terminal GEF
domain of the multidomain Trio protein, and identified
ITX3 as a nontoxic inhibitor. In transfected mamma-
lian cells, ITX3 blocked TrioN-mediated dorsal me-
mbrane ruffling and Rac1 activation while having no
effect on GEF337-, Tiam1-, or Vav2-mediated RhoA
or Rac1 activation. ITX3 specifically inhibited endoge-
nous TrioN activity, as evidenced by its ability to
inhibit neurite outgrowth in nerve growth factor
(NGF)–stimulated PC12 cells or C2C12 differentiation
into myotubes. This study introduces a selective cell
active inhibitor of the Trio/RhoG/Rac1 pathway and
validates RhoGEFs as druggable targets.
INTRODUCTION
RhoGEFs promote the exchange of GDP with GTP on Rho
GTPases and are frequently associated with membrane receptor
complexes. As such, they represent major entry points allowing
cross-talk between extracellular cues and Rho signaling
cascades. In mammals, RhoGEFs include the Dbl-like and the
Dock protein families. Dbl-like proteins, with over 70 members,
all have a catalytic Dbl homology (DH) domain and a pleckstrin
homology (PH) domain involved in phospholipid or protein
binding; the Dock family comprises 11 members, all with a cata-
lytic Dock homology region (DHR2) and a Ca2+-dependent phos-
pholipid binding (C2) domain (Rossman et al., 2005; Cote and
Vuori, 2007).
Over the last decade, RhoGEF and Rho members have
emerged as key factors in the progression of many cancer types
(Ellenbroek and Collard, 2007; Vega and Ridley, 2008). This is
consistent with the known roles of Rho proteins in the control
of basic cell structures, in particular the respective roles of
RhoA, Rac1, and Cdc42 in the formation of F-actin stress fibers,
lamellipodia, and filopodia in all multicellular organisms (Jaffe
and Hall, 2005; Boureux et al., 2007). Rho proteins thus modulateChemistry & Biology 16cell adhesion, polarity, migration, contraction, proliferation, and
apoptosis in a number of normal and pathological processes,
from cell movements in the developing embryo to common
diseases, such as hypertension, cancer, or neurodegenerative
diseases (Shirai et al., 2007; Fritz and Kaina, 2006). In contrast
to Ras proteins, which are activated by somatic mutations in
many tumor types (Diaz-Flores and Shannon, 2007), Rho path-
ways are mostly activated in tumors as a consequence of
GTPase or GEF overexpression (Vega and Ridley, 2008).
Rho signaling components are therefore attractive targets for
the development of inhibitory drugs (Fritz and Kaina, 2006);
indeed, various chemical inhibitors have been identified acting
at different points of Rho signaling: FTI (Kohl et al., 1993), which
inhibits the transfer of isoprenyl lipids that anchor Rho GTPases
in membranes; NSC23766 (Gao et al., 2004), which targets a Rac
region involved in the binding to GEFs; and EHT 1864 (Shutes
et al., 2007), which binds to Rac and destabilizes the bound
nucleotide. Inhibitors that target effectors were also developed:
Y27632 (Uehata et al., 1997), which inhibits the RhoA effector
ROCK; and IPA-3 (Deacon et al., 2008), which inhibits the Rac/
Cdc42 effector PAK kinases. Several inhibitors are already in
clinical use, such as fasudil, which targets ROCK for the treat-
ment of cerebral vasospasm and angina (reviewed in Olson,
2008), and nitrogen-containing biphosphonates, which indirectly
inhibit isoprenoid biosynthesis for the control of hypercalcemia,
osteoporosis, and bone cancer metastasis (reviewed in Russell
et al., 2007).
Although considered to be promising therapeutic targets, the
only RhoGEF inhibitors identified so far act against Trio, a multi-
domain protein implicated in neurogenesis, phagocytosis, and
myogenesis (Lin and Greenberg, 2000; Henson, 2005; Charrasse
et al., 2007; Brianc¸on-Marjollet et al., 2008). Trio is unusual in that
it contains two RhoGEF domains: one N-terminal domain (TrioN),
active on RhoG/Rac1 (Blangy et al., 2000), and a C-terminal
domain (TrioC), active on RhoA (Debant et al., 1996). Trio is
involved in the invasive behavior of glioblastoma and breast
cancers (Lane et al., 2008; Salhia et al., 2008), while Tgat, an
alternative Trio isoform derived from TrioC, was identified as
a new oncogene in adult T-leukemia (Yoshizuka et al., 2004).
To date, two types of Trio inhibitors have been characterized:
Tripa and derived peptides, which associate with and inhibit
TrioC (Schmidt et al., 2002; Bouquier et al., 2009), and NPPD,
a compound that is biochemically active on TrioN and that we
previously identified from a screen for RhoGEF inhibitors in a per-
meant yeast strain (Blangy et al., 2006)., 657–666, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 657
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A Cell Active Inhibitor of Trio/RhoG/Rac SignalingFigure 1. ITX1 Compound Is a Nontoxic
Inhibitor of RhoG Activation by TrioN
(A) Upper panel: REF 52 cells were cultured for
24 hr or 48 hr in 10% FCS alone (-) or supple-
mented with 1% DMSO, 100 mM NPPD in 1%
DMSO, or ITX1 in 1% DMSO. Histograms repre-
sent cell viability, defined as the ratio of Trypan
Blue negative cells versus total cell number. Lower
panel: REF 52 cells were cultured for 24 hr in the
same conditions as above then stained with
Crystal violet.
(B) ITX1 and NPPD chemical structures.
(C) In vitro exchange kinetics were performed by
measuring the increase in fluorescence emitted
with time upon incorporation of Mant-GTP into
1 mM RhoG alone (no TrioN) or with 0.1 mM TrioN
in the presence of 0, 25, 50, or 100 mM ITX1 in
1% DMSO. Mant-GTP exchange is expressed as
relative fluorescence units (RFU).We show here that NPPD is toxic in mammalian cells and iden-
tify a new chemical compound isolated from the same screen.
We demonstrate that this compound is active in several cell lines,
blocking cellular responses to exogenously expressed TrioN or
endogenous Trio, and thus disrupting various physiological
processes.
RESULTS
Identification of a Nontoxic Compound, Inhibiting
TrioN In Vitro GEF Activity
We previously screened a library of 3,500 chemical compounds
using a GEF activity assay in permeant yeast cells and identified
1-(3-nitrophenyl)-1H-pyrrole-2,5-dione (NPPD) as a potent in-
hibitor of TrioN activity on RhoG and Rac1 in vitro (Blangy
et al., 2006). In this study, NPPD was toxic when applied to
mammalian REF-52 cells, killing 70% of the treated cells after
a 24 hr treatment, and killing up to 90% of cells after 48 hr, as de-
tected by trypan blue staining (Figure 1A). We thus assayed the
toxicity of other compounds isolated from the initial screen and
selected 2-(5-chloro-2-ethoxybenzylidiene) [1,3] thiazolo[3,2-a]
benzimidazol-3(2H)-one (from now on referred to as ITX1,
for Inhibitor of Trio eXchange 1) for its absence of toxicity in
REF-52 cells (Figure 1A). ITX1 is structurally distinct from
NPPD (Figure 1B). We confirmed that ITX1 indeed inhibited
TrioN-mediated GTP exchange on RhoG in vitro, as demon-
strated by the dose-dependent inhibition of Mant-GTP loading
on RhoG (Figure 1C).
Secondary Screening of ITX1 Analogs
We next performed a search in the PubChem database to
examine whether compounds showing structural features similar
to ITX1 had already been used in other bioassays. Of 349
compounds with structures related to the initial compound
ITX1 (CID 1919674), only 34 had been previously tested and
found to be inactive in seven different bioassays (screens for
inhibitors of EphA4 receptor, Hsp70, HePTP tyrosine phospha-
tase, MKP3 dual specificity phosphatase, Bcl-B converters, ER
stress-induced apoptosis, or HIV-1 RNase H). Thus, despite their
high frequency in libraries, compounds related to ITX1 have not
been identified as efficient inhibitors of other targets. We658 Chemistry & Biology 16, 657–666, June 26, 2009 ª2009 Elseviecollected a series of ITX1 structural analogs and tested their
ability to inhibit TrioN-stimulated RhoG exchange in vitro
(Figure 2). Of thirteen analogs, seven showed inhibitory activities
higher than or similar to that of ITX1 (ITX2-8), whereas the other
six showed little activity. Comparison of IC50 for the most active
compounds showed that only ITX2 is statistically significantly
more potent than ITX1. ITX14 showed an IC50 six to fifteen times
lower than those of active compounds and was used from now
on as a negative control analog. ITX2 was not investigated
further because of its elevated background fluorescence in
microscopy analysis of cultured cells. However, the higher effi-
cacy of ITX2 suggests that substitutions on the benzene cycle
of the benzylidene moiety have no positive effects (compared
with ITX1 and ITX8) and may even reduce the inhibitory activity
(compared with ITX10 and ITX14). Single-change variants of
ITX2 will be needed for a comprehensive structure activity rela-
tionship analysis.
Biochemical Analysis of ITX Compounds
We next confirmed the dose-dependent inhibition of GTP
exchange for two analogs of different strengths (ITX3 and
ITX14) over a 10 min time course. ITX3 (Figure 3A, left panel)
showed clear dose-dependent inhibition throughout kinetics
with a higher level of efficiency than ITX1 (see Figure 1B),
whereas ITX14 (Figure 3A, right panel) had little effect, as ex-
pected from the data described above (Figure 2). TrioN also
promotes GTP exchange on Rac1, although to a lesser extent
than on RhoG (Blangy et al., 2000); thus, we investigated whether
ITX1 analogs also inhibit TrioN activity on Rac1 in a 10 min time
course experiment. ITX3 and ITX1 compounds inhibited TrioN-
stimulated GTP exchange on Rac1 by 45% to 50%, whereas
ITX14 had no effect (Figure 3B). This finding demonstrates that
ITX compounds inhibit TrioN stimulation of both GTPases to
the same extent. We next examined whether ITX1 analogs
have a direct effect on the affinity of RhoG for Mant-GTP, as
observed for the Rac1 inhibitor EHT 1864. To this end, we
analyzed the nucleotide release kinetics for RhoG preloaded
with Mant-GTP (Figure 3C). In the absence of TrioN, fluores-
cence remained stable throughout the experiment (i.e., 900 s)
and was insensitive to the presence of ITX1, ITX3, or ITX14;
thus, the stability of the bound nucleotide did not seem to ber Ltd All rights reserved
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A Cell Active Inhibitor of Trio/RhoG/Rac SignalingFigure 2. Secondary Screening of ITX1 Analogs
For each analog, the chemical structure and a histogram representing the percentage of inhibition of RhoG activation by TrioN are shown at various analog
concentrations, as illustrated in the top left panel. Fluorescence was measured after a 15 min reaction. For ITX1-4, ITX8, and ITX14, means and standard devi-
ations from three experiments are represented on histograms and IC50 are shown (** indicate IC50 significantly different from ITX1 IC50, Mann-Whitney p < 0.01).affected by these compounds. ITX3 inhibited the TrioN-stimu-
lated release of Mant-GTP by 50%, suggesting that ITX3 affects
the first steps of the exchange reaction, during which the bound
nucleotide is released.
ITX3 Inhibition of TrioN Signaling In Vivo
We next examined whether the ITX1 analogs showing in vitro
inhibitory activity are active on mammalian cells. We tested the
effects of these compounds on TrioN-induced formation of
particular F-actin membrane structures (Blangy et al., 2000). In
rat embryo fibroblasts REF-52, 72% of TrioN-expressing cells
showed extensive dorsal ruffling associated with loss of actin
stress fibers, 28% of TrioN-expressing cells showed peripheral
lamellipodia with reduced stress fiber content, and less than
1% displayed only small or no changes in F-actin structure
(Figure 4A). We analyzed ITX1 and four analogs of higher (ITX3
and ITX4), similar (ITX8), or lower (ITX14) in vitro inhibition
efficiency (see Figure 2). ITX5 could not be tested because of
insufficient amounts available. Of the five compounds, only
ITX3 significantly suppressed the TrioN-induced phenotype
(Figure 4B): stress fibers were present in 15% of TrioN-express-Chemistry & Biology 16ing cells (versus <1% in untreated cells), the extent of dorsal
ruffling was lower than that in untreated cells (31% versus
72%), and these protrusions appeared displaced toward periph-
eral lamellipodia in 54% of cells (versus 28% in untreated cells).
Consistent with their biochemical effects on TrioN-stimulated
GTP exchange, ITX3 inhibited the formation of TrioN-dependent
cell structures in a dose-dependent manner, whereas the ITX14,
which was inactive in vitro, had no significant effect (Figure 4C).
Specificity of ITX3 Inhibition
To address the specificity of ITX3 inhibition, we first examined
whether the inhibition of TrioN-induced phenotypic responses
by ITX3 in REF52 cells correlated with a reduced level of active
Rac. TrioN activates Rac either directly or indirectly through
RhoG activation (Katoh and Negishi, 2003; Gauthier-Rouviere
et al., 1998). We observed higher levels of active Rac in
HEK293T cells expressing GFP-TrioN than in cells expressing
GFP alone (Figure 5A, compare lanes 1 and 2). These elevated
levels of Rac activity were reduced by 80% in the presence of
ITX3 (lane 3), whereas the inactive ITX14 analog had no effect
(lane 4). We next compared the specificity of ITX3 toward other, 657–666, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 659
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A Cell Active Inhibitor of Trio/RhoG/Rac SignalingFigure 3. In Vitro Analysis of ITX3 Inhibition
(A) In vitro exchange kinetics were performed by measuring the increase in fluorescence emitted with time upon incorporation of Mant-GTP into 1 mM RhoG alone
(no TrioN) or with 0.1 mM TrioN in the presence of 0, 12.5, 25, 50, or 100 mM ITX3 (left panel) or ITX14 (right panel).
(B) In vitro exchange kinetics were measured from incorporation of Mant-GTP into 1 mM Rac1 without (no TrioN) or with 1 mM TrioN in the presence of DMSO alone
or containing 100 mM ITX1, ITX14, or ITX3.
(C) In vitro exchange kinetics were performed by measuring the decrease in fluorescence emitted with time from 1 mM preloaded Mant-GTP-RhoG either in the
presence of ITX1, ITX3, ITX14, or DMSO or in the presence of 0.3 mM TrioN alone or in combination with 100 mM ITX3.RhoGEFs and Rho GTPases. Among the twenty Rho family
members in mammals (Boureux et al., 2007), only GEFs for
RhoA-C, RhoG, Rac, and Cdc42 have been identified. We thus
examined the effect of ITX3 on the exchange activity of
GEF337, a RhoA-specific GEF (De Toledo et al., 2000); Tiam1,
a Rac-specific GEF (Michiels et al., 1995); and Vav2, a GEF active
on Rac1, RhoA, and Cdc42 (Abe et al., 2000) (Figure 5B). ITX3
treatment had no effect either on RhoA activation by GEF337 or
on Rac1 activation by Tiam1 and only showed a modest effect
on Rac1 activation by Vav2. ITX3 inhibition thus seems to be
specific for TrioN rather than other RhoGEFs.
ITX3 Inhibition of Trio-Dependent Neurite Outgrowth
Trio is an evolutionarily conserved multifunctional protein, the
depletion of which in the mouse induces secondary defects in
myofibers and aberrant organization of brain tissues (O’Brien
et al., 2000). Ex vivo, Trio plays essential roles in neurite
outgrowth and axon guidance in insect and mammalian neuronal
cells (Newsome et al., 2000; Estrach et al., 2002; Bateman et al.,
2000; Brianc¸on-Marjollet et al., 2008). NGF treatment of rat PC12660 Chemistry & Biology 16, 657–666, June 26, 2009 ª2009 Elseviephaeochromocytoma cells stimulates neurite outgrowth through
activation of the Trio/RhoG-dependent pathway, eventually
leading to Rac1 and Cdc42 activation (Estrach et al., 2002).
We therefore used this cell system to determine the capacity of
ITX3 to inhibit GTP exchange stimulated by the TrioN domain
of endogenous Trio. In a typical experiment, about 40% of
NGF-treated PC12 cells produced cellular extensions (panel
DMSO, Figure 6). ITX3 treatment reduced the number of cells
with neurite outgrowth by 50%, whereas the inactive ITX14
analog did not affect the NGF response (histogram, Figure 6).
These data therefore confirm the action of ITX3 as an inhibitor
of the TrioN domain of endogenous Trio.
TrioN Requirement for Myoblast Fusion
During skeletal myogenesis, myoblasts arrest in G1 in response
to external cues, express myogenic factors such as myogenin or
troponinT, and then fuse to form myotubes. Trio participates in
the fusion of C2C12 myoblasts; indeed, C2C12 cells expressing
Trio shRNA are unable to form myotubes (Charrasse et al., 2007).
However, Trio knockdown may have broader effects than simpler Ltd All rights reserved
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A Cell Active Inhibitor of Trio/RhoG/Rac SignalingFigure 4. Inhibition of TrioN-Mediated REF52 Cell Structures by ITX1 Analogs
(A) TrioN-expressing REF52 cells were examined for F-actin distribution (upper row) and GFP fluorescence (lower row). F-actin structures and frequencies are
indicated.
(B) TrioN-expressing REF52 cells were treated for 24 hr with 1% DMSO either alone (DMSO) or containing 100 mM of the indicated ITX1 analogs. Cells were
stained for F-actin and scored for F-actin structures. White bars, dorsal ruffles; gray bars, peripheral lamellipodia; and black bars, stress fibers.
(C) Dose response analysis of ITX3 and ITX14. TrioN-expressing REF52 cells were treated for 24 hr with 1% DMSO containing 5, 10, 25, 50, or 100 mM ITX3 (active)
or ITX14 (inactive). Cells were scored as in B. Histogram shows means and standard deviations of three independent experiments.inhibition of TrioN activity. We therefore examined the effects of
ITX3 on the fusion process. Cellular differentiation, determined
by the induction of myogenin and troponin-T, did not differ
between ITX3-treated C2C12 cells and control (DM) or DMSO-
treated (DMSO) cells (Figure 7A). Given that these early events
require RhoA activation (Wei et al., 1998), this suggests that
ITX3 does not significantly affect RhoA-dependent pathways.
However, myotube formation was inhibited in a dose-dependent
manner in ITX3-treated cells, as detected by fusion index anal-
ysis (Figure 7B). We observed a similar extent of inhibition using
100 mM ITX3, 100 mM NSC23766 (a Rac1 inhibitor), or Trio
knockdown. We then examined cell morphology; C2C12 cells
incubated with 100 mM ITX3 failed to align and fuse (Figure 7C,
panel b). C2C12 cells knocked down for Trio or treated with
ITX3 showed a similar overall flat morphology with loose cell
contacts (compare panels b and d), whereas cells treated with
NSC23766 appeared refringent and more packed (panel c).
NSC23766 was designed to target a surface groove in Rac1 crit-
ical for interaction with GEFs; thus, NSC23766 may target
additional RhoGEFs that are involved in C2C12 cell morphology
and are insensitive to ITX3. Taken together, our findings demon-
strate that TrioN activity controls myotube formation duringChemistry & Biology 16skeletal myogenesis and suggest that ITX3 acts specifically on
this GEF domain.
DISCUSSION
Given the large number of Rho components encoded in the
human genome (20 GTPases, over 80 GEFs, and over 50
GAPs), inhibitors targeting specific pathways would provide
useful tools for basic functional studies and for subsequent
development of therapeutic drugs. In this study, we identified
ITX3, a compound active in cells that inhibits TrioN-induced
in vitro nucleotide exchange on RhoG and Rac1, formation of
TrioN-induced cellular structures in REF52 fibroblasts, and
NGF-induced neurite outgrowth in PC12 cells, a process medi-
ated by TrioN, RhoG, and Rac1. ITX3 also inhibits fusion of
C2C12 myoblasts during the formation of myotubes, which evi-
denced that TrioN activity is required for this process. To the
best of our knowledge, ITX3 has not been previously shown to
be active in any other bioassay and therefore represents a new
chemical compound able to inhibit Rho signaling.
The ITX3 compound showed clear specificity for the inhibition
of TrioN, rather than other RhoGEFs: it had no effect on RhoA, 657–666, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 661
Chemistry & Biology
A Cell Active Inhibitor of Trio/RhoG/Rac SignalingFigure 5. Specificity of ITX3 Inhibition
(A) TrioN-expressing HEK293T cells were treated for 1 hr with 1% DMSO alone or containing 50 mM ITX3 or ITX14 and then were lysed. GTP-bound Rac was
affinity-purified on PAK-CRIB sepharose beads, analyzed by Western blotting, and normalized to total Rac. Expression of empty pEGFP-C1 vector was used
as a negative control.
(B) Left panel: GEF337-expressing HEK293T cells were processed as in A except that GTP-bound RhoA was affinity-purified on Rhotekin-RBD sepharose beads.
Right panel: TrioN-, Tiam1-, or Vav2-expressing HEK293 cells were processed as in A. For panels A and B, images show representative Western blotting exper-
iments, and histograms represent means and standard deviations of densitometric analyses of three independent experiments.activation by GEF337 or on Rac activation by Vav2 or Tiam1. We
also demonstrated this specificity indirectly: REF52 cells ex-
pressing TrioN and treated with ITX3 were still able to form
F-actin stress fibers, a process that requires Rho A-C activation.
This finding strongly suggests that GEFs acting on these
GTPases are not affected by ITX3. Similarly, ITX3 treatment
impaired the terminal fusion process in C2C12 differentiation
but did not affect myogenic commitment, an early step that
requires RhoA activation and the activity of GEFT, a GEF for
RhoA/Rac1/Cdc42 (Bryan et al., 2005; Guo et al., 2003; Wei
et al., 1998).
We used a screening procedure designed to select inhibitors
that specifically block the activation of RhoG by TrioN. As such,
inhibitors were expected to target either RhoGEF, GTPase, or
RhoGEF/GTPase complexes. The inhibitor EHT 1864 has a direct
effect on the bound nucleotide (Shutes et al., 2007); however, this
does not appear to be the case for ITX compounds, since they
had no effect on stability of the GTPase-nucleotide complex
in vitro. We also observed that ITX3 inhibited TrioN activity
in vitro to the same extent in Mant-GTP loading assays on
GDP-bound RhoG and in release assays with Mant-GTP pre-
loaded RhoG (Figures 3A and 3C). GEF-mediated nucleotide
exchange is a multistep process, which is initiated by formation
of a low-affinity complex between the GEF and the nucleotide-
bound GTPase (Renault et al., 2003). This initiation step promotes
nucleotide release and leads to formation of a high-affinity662 Chemistry & Biology 16, 657–666, June 26, 2009 ª2009 Elseviecomplex between the GEF and the nucleotide-free GTPase.
Our observation that ITX3 prevents Mant-GTP release from pre-
loaded RhoG thus demonstrates that ITX3 disrupts initiation
steps, impairing either formation of the low-affinity complex or
release of the nucleotide from the formed complex. This is
suggestive of a mechanism potentially similar to NSC23766,
which binds competitively to the GEF/GTPase interface, rather
than to EHT 1864, which induces destabilization of the GTPase/
nucleotide complex. Our data also strongly suggest that ITX3
and NSC23766 target distinct proteins. Indeed, NSC23766
inhibits TrioN- and Tiam1-mediated Rac1 activation (Gao et al.,
2004), whereas ITX3 has no effect on Tiam1 (Figure 5B). Effects
of NSC23766 on both Tiam1 and TrioN are consistent with the
model in which this compound targets a Rac1 groove that faces
the DH domain of either Tiam1 or TrioN and is thus critical for
formation of the exchange complexes (Worthylake et al., 2000;
Chhatriwala et al., 2007). ITX3 specificity for TrioN and not for
Tiam1 therefore implies that this compound does not target the
same Rac1 interface, as it would otherwise inhibit the action of
Tiam1 on Rac1. Moreover, ITX3 inhibits TrioN stimulation of
RhoG and Rac1 to the same extent. These two GTPases are
highly conserved (89% similar) in the region at the interface of
TrioN (only 63% similarity outside this region—that is, in their
117 C-terminal amino-acid sequence). It therefore seems unlikely
that ITX3 targets a region poorly conserved between RhoG or
Rac, which is located outside of the TrioN interface and yet isr Ltd All rights reserved
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hypothesis is that ITX3 targets TrioN, consistent with the speci-
ficity for TrioN versus Tiam1 and the dual inhibition of TrioN
exchange on RhoG and Rac1.
Rac1 is ubiquitously expressed and is required at early stages
of development (Sugihara et al., 1998). In adults, the roles of Rac
proteins have mostly been investigated in the immune system,
with studies of tissue-restricted depletion of both Rac1 and
Rac2 showing many resulting hematopoietic defects (Kalfa
et al., 2006; Dumont et al., 2008; Ramaswamy et al., 2007). Inhi-
bition of the overall activity of Rac proteins by drugs such as EHT
1864 can thus have major effects when used as a systemic ther-
apeutic treatment. It should therefore be used only for specific
diseases, such as breast or colorectal cancers, that produce
Rac1b, an isoform that is constitutively activated in a GEF-inde-
pendent manner (Stallings-Mann and Radisky, 2007; Matos and
Jordan, 2008). Inhibition of Rac activation by drugs such as
NSC23766 may have more specific effects, with only a subset
of RhoGEFs affected. NSC23766 was indeed shown recently
to attenuate the severity of disease in a murine model of p120
Bcr-Abl-induced chronic myelogenous leukemia, which involves
Rac activation (Thomas et al., 2007). Suppression of GEF
activity, the likely mode of action of ITX3, may have even more
specific effects, particularly for GTPases such as RhoG and
Rac1, which are activated by multiple GEFs. Trio preferentially
activates RhoG, which, in turn, activates Rac through the
ELMO/DOCK180 complex (Katoh and Negishi, 2003). The direct
targeting of the TrioN domain would therefore block the down-
stream RhoG/Rac activation pathway without affecting activa-
tion of either GTPase by other GEFs. Such selectivity may be
Figure 6. ITX3 Inhibition of NGF-Induced Neurite Outgrowth
GFP-expressing PC12 cells were stimulated with 50 ng$ml1 NGF for 36 hr in
the presence of 1% DMSO alone or in combination with 100 mM ITX3 or ITX14.
Cells were counted for the presence or absence of neurites of at least twice the
cell body length. Scale bar: 10 mM. Graph shows the ratio of cells with neurites
relative to NGF-treated control cells, as determined from four experiments.
Error bars indicate standard deviation.Chemistry & Biology 16of interest in particular cancers (e.g., glioblastoma and breast
cancers) in which Trio plays a role in their invasive behavior
(Lane et al., 2008; Salhia et al., 2008).
SIGNIFICANCE
Rho signaling pathways control many aspects of cell
dynamics and are frequently found activated in a variety of
diseases such as hypertension and cancer. Signaling is initi-
ated by RhoGEFs, which activate one or more Rho GTPases.
TheseGTPases in turn activatemultiple effectors to produce
their cellular effects. RhoGEFs are thus attractive targets for
modulating the intensity of response to specific upstream
signals. However, the only Rho signaling inhibitors currently
available for in vivo use target GTPases or their effectors.We
used an engineered yeast strain to select for inhibitors that
block RhoGEF-dependent Rho GTPase activation. We iden-
tified ITX3, a compound that is active in cells and inhibits the
activity of TrioN, one of the two Dbl-like domains of Trio.
ITX3 displays specificity, having no effect on RhoA activa-
tion by GEF337 or Rac1 activation by Tiam1 and Vav2. ITX3
inhibited NGF-induced neurite outgrowth, confirming the
pivotal role of the TrioN domain of endogenous Trio in this
process. Moreover, ITX3 treatment of differentiating C2C12
myoblasts demonstrated that TrioN activity of endogenous
Trio is also needed for membrane fusion during myotube
formation. These data demonstrate that the screening
method we developed in yeast is suitable for identifying
RhoGEF inhibitors and validate ITX3 as a lead compound
for inhibiting specific endogenous RhoGEF domains in living
cells. The availability of bioactive compounds targeting
endogenous RhoGEF activity will open up new perspectives,
allowing differential regulation of specific signaling path-
ways involved in disease progression.
EXPERIMENTAL PROCEDURES
Plasmids, Recombinant Proteins
Bacterial expression vectors and protein purification methods were described
earlier (Blangy et al., 2006). Eukaryotic cell constructs were described else-
where (Blangy et al., 2000; De Toledo et al., 2001; Charrasse et al., 2006; Mich-
iels et al., 1995; Crespo et al., 1997). Tiam1 and Vav2 vectors were gifts from
J. Collard and X. Bustelo, respectively.
Cell Lines, Transfection, and Immunofluorescence
Rat embryonic fibroblasts (REF-52) were cultured at 37C in the presence of
5% CO2 in Dulbecco’s modified Eagle’s medium supplemented with 10%
(v/v) fetal calf serum (FCS) as described by Blangy et al. (2000). Cells were
plated on 12 mm glass coverslips 16–24 h before being transfected using the
JetPEI reagent as described by the supplier (Polyplus Transfection). Four hours
after transfection, cells were incubated with fresh medium containing 1%
DMSO (v/v) and chemical compounds at various concentrations. Twenty-
four hours later, cells were fixed for 10 min in 3.7% (v/v) formalin in PBS. After
a 2 min permeabilization in 0.1% Triton X-100 in PBS and a 30 min incubation at
20C in 0.1% BSA in PBS, cells were stained for actin using ACMA (amino-
methyl coumarin)–conjugated phalloidin (0.5 unit/ml; Sigma). Cells were
washed in PBS and mounted in Mowviol (Aldrich) and observed using a DMR
Leica microscope with a 633 planochromat lens. Images were recorded using
a Coolsnap HQ2 CCD (charge-coupled-device) camera (Princeton Instru-
ments) and transferred to Adobe Photoshop. Transfections were repeated at
least three times and an average of 100 cells was examined., 657–666, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 663
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(A) Wild-type or Trio knocked-down C2C12 cells were induced to differentiate for one to four days (d1 to d4) in differentiation medium (DM), alone or in the pres-
ence of 1% DMSO, 100 mM ITX3 or 100 mM NSC23766, as indicated. Cells extracts were analyzed for Myogenin and Troponin T expression. b-tubulin was used as
a loading control.
(B) C2C12 were induced to differentiate for four days in the presence of 1% DMSO alone or in combination with ITX3 at various concentrations or in the presence
of 100 mM NSC23766. C2C12 cells knocked-down for Trio (Trio shRNA) were used as a control. Histogram represents the fusion index—that is, the ratio of nuclei
in multinucleated myotubes to total nuclei, calculated from four independent experiments. In each experiment, at least 1000 nuclei were counted. Only cells with
a minimum of three nuclei were considered as myotubes. Error bars indicate standard deviation.
(C) Phase-contrast images of C2C12 myoblasts representative of experiments described in B. Scale bar: 30 mM.PC12 cells were seeded onto collagen type I (Sigma)–coated glass cover-
slips in 6-well plates at a density of 5 3 105 cells per well and were cultured
for 18 hr in DMEM containing 5% FCS and 10% horse serum (HS). Cells
were transfected for 8 hr with 1 mg of total DNA using JetPEI reagent. Trans-
fection mix was then replaced with differentiation medium (DMEM with 50
ng$ml1 NGF (Promega) and 0.5% HS) containing 1% DMSO (v/v) or 1%
DMSO containing 100 mM chemical compounds for 36 hr prior to fixation.
C2C12 mouse myoblasts were grown in DMEM/Ham’s F-12 (1:1) supple-
mented with 10% FCS. Differentiation was induced by replacing growth
medium with differentiation medium consisting of DMEM/Ham’s F-12 supple-
mented with 2% FCS. C2C12 cells stably expressing Trio shRNA (Charrasse
et al., 2007) were cultured under the same conditions in medium supple-
mented with 200 mg$ml1 Hygromycin B; 0.5% DMSO (v/v), 0.5% DMSO con-
taining 10 to 100 mM chemical compounds, or the Rac1 inhibitor NSC23766
(Calbiochem, La Jolla, CA) were added 1 hr after addition of the differentiation
medium. Medium with compounds was renewed every day for 5 days before
fixation and Hoechst and F-actin staining. The fusion index was defined as the
number of nuclei in multinucleated myotubes divided by the total number of
nuclei. At least 1000 nuclei were counted using the MRI Cell Image Analyzer
program (Baecker and Travo, 2006). All chemical compounds were purchased
from ChemBridge (San Diego, CA).
Rac-GTP and RhoA-GTP Pulldown Experiments
HEK293T cells were transfected with the indicated plasmids for 24 hr, incu-
bated for 1 hr in the presence of 1% DMSO containing or not the inhibitory
compounds then lysed. For Rac1 activity assay, cells were lysed in 25 mM
HEPES (pH 7.5), 1% Igepal, 5% glycerol, 100 mM NaCl, 10 mM MgCl2,
5 mM NaF, 1 mM Na3VO4, 1mM Leupeptin/Aprotinin, and 1 mM AEBSF.664 Chemistry & Biology 16, 657–666, June 26, 2009 ª2009 ElsevierCleared lysate was incubated with 25 mg of GST-Pak CRIB bound to gluta-
thione-coupled Sepharose beads for 45 min at 4C. Beads were washed three
times in 25 mM HEPES (pH 7.5), 0.5% Igepal, 40 mM NaCl, 30 mM MgCl2, and
1 mM DTT before addition of Laemmli sample buffer. For RhoA activity assay,
cells were lysed in 50 mM TrisHCl (pH 7.2), 1% Triton X-100, 500 mM NaCl,
10 mM MgCl2, 1 mM Leupeptin/Aprotinin, and 1 mM AEBSF. Cleared lysate
was incubated with 50 mg of GST fused RhoA-binding domain of Rhotekin
(GST-RBD) bound to glutathione beads for 45 min at 4C. Beads were then
washed four times in 50 mM TrisHCl (pH 7.2) containing 1% Triton X-100,
150 mM NaCl, 10 mM MgCl2, 1 mM Leupeptin/Aprotinin, and 1 mM AEBSF
before addition of Laemmli sample buffer. Total cell lysates and proteins
bound to beads were resolved on 15% SDS/PAGE and immunoblotted using
anti-Rac1 (Transduction Laboratory) or anti-RhoA antibodies (Santa Cruz
Biotechnology, Inc.). Quantification of activation was performed by densito-
metric analysis using the Aida/2D densitometry software (Raytest, Strauben-
hardt). The relative amount of active protein was determined as the amount
of protein sedimented relative to the amount in whole cell lysates.
In Vitro Exchange Assays
Fluorescence-based guanine nucleotide-exchange assays were performed
using Mant-GTP (Molecular Probes) in an FLX 800 microplate fluorescence
reader (BioTek Instruments) at 25C. Nucleotide exchange was measured by
measuring either Mant-GTP loading or Mant-GTP release from a preloaded
GTPase. Mant-GTP loading mixtures containing 0.1 mM or 1 mM GEF were
incubated for 30 min at 25C in reaction buffer (20 mM TrisHCl [pH 7.5],
50 mM NaCl, 2 mM MgCl2, 1 mM Mant-GTP, and 50 mg/ml BSA) containing
5% DMSO and the inhibitor at the desired concentration. The exchange reac-
tion was started by addition of 1 mM GTPase. The relative Mant fluorescenceLtd All rights reserved
Chemistry & Biology
A Cell Active Inhibitor of Trio/RhoG/Rac Signaling(lex = 360 nm and lem = 460 nm) was monitored for 15 min, and measurements
were taken every 10 s. Alternately, GTPases were preloaded with Mant-GTP
for 15 min at 25C in reaction buffer supplemented with 2.5 mM EDTA then
stabilized with 10 mM MgCl2. The exchange reaction was started by addition
of 0.3 mM GEF, 1 mM GTP and 5% DMSO and the inhibitor at the desired
concentration. IC50 values were determined from triplicate data using Graph-
pad Prism 4 software. Sigmoidal fitting was done using built-in functions.
Statistical analysis of IC50 values was made using the nonparametric Mann-
Whitney test. The level of significance was set at p < 0.01.
Toxicity Assays
REF 52 cells were seeded in 24-well plates at a density of 4.104 cells/well in
DMEM containing 10% fetal bovine serum and were cultured for 24 hr; 1%
DMSO (v/v) or 1% DMSO containing 100 mM chemical compounds were
added for 24 hr or 48 hr. Cells were then either trypsinized and stained with
0.2% Trypan Blue or directly stained with 1% Crystal Violet (Sigma-Aldrich).
Percentage of cell viability was defined as the ratio of negative blue cells
versus the total number of cells.
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